Minerva Neurosciences Reports Q4 and FY2025 Financial Results and Major Business Updates

Key Highlights

• Initiation of Confirmatory Phase 3 Trial for Roluperidone Set for Q2 2026
• Substantial \$80 Million Upfront Financing Secured in October 2025, with Additional Potential Proceeds up to \$120 Million
• Significant Non-Cash Accounting Impacts from Preferred Stock and Warrant Transactions
• Cash Position Strong at \$82.4 Million at Year-End 2025
• Net Loss Largely Attributable to Non-Cash Charges; Core Operating Expenses Remain Tight

Business and Clinical Development Updates

Minerva Neurosciences (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on therapies for central nervous system disorders, announced its Q4 and full-year 2025 financial results along with crucial business updates.

Upcoming Phase 3 Confirmatory Trial for Roluperidone

• The company is preparing to launch a pivotal confirmatory Phase 3 trial of roluperidone for the treatment of negative symptoms of schizophrenia in the second quarter of 2026.
• Topline data from the 12-week efficacy endpoint is anticipated in the second half of 2027.
• Minerva has achieved “general alignment” with the U.S. Food and Drug Administration (FDA) regarding the trial design, which is expected to closely follow the company’s previous studies.
• The study will enroll approximately 380 patients and will first assess efficacy over 12 weeks, followed by a safety phase comparing relapse rates for patients on roluperidone vs. antipsychotics.
• If successful, roluperidone could become the first ever treatment approved specifically for negative symptoms of schizophrenia, an area of high unmet medical need.

Financing and Capital Structure

• On October 23, 2025, Minerva secured \$80 million in gross proceeds through a private placement, with possible access to an additional \$80 million via Tranche A warrant exercises, and another \$40 million from Tranche B warrants contingent on meeting the Phase 3 trial’s primary endpoint.
• The upfront funds and potential warrant exercises are expected to provide sufficient cash to complete the Phase 3 trial and resubmit the New Drug Application (NDA) for roluperidone, with the aim of a U.S. launch if approved.

Financial Results & Major Accounting Events

Operating Expenses

• R&D Expense: \$2.2 million for Q4 2025 (up from \$2.0 million in Q4 2024), primarily due to higher consultant fees. For the full year, R&D expense was \$5.8 million (down from \$11.9 million in 2024 due to lower drug validation and safety study costs).
• G&A Expense: \$2.8 million for Q4 2025 (up from \$2.5 million in Q4 2024), mainly due to increased compensation expenses, partially offset by lower insurance costs. Full-year G&A was \$9.3 million (down from \$9.9 million in 2024).

Impactful Non-Cash Transactions

• Convertible Preferred Stock and Warrants: The company issued 80,000 shares of Series A Convertible Preferred Stock (convertible into 37.8 million common shares) and warrants for up to 120,000 more preferred shares (convertible into 56.8 million shares) in the October 2025 private placement.
• These instruments resulted in a significant non-cash loss of \$321.5 million, reflecting their fair value offset by the cash received.
• Warrant liabilities are marked to market each period; a \$45.4 million non-cash gain was recognized in Q4 due to the decline in fair value of these warrants.

Other Financial Items

• Non-Cash Interest Expense: None recognized in 2025 following a major adjustment in 2024 related to the Royalty Pharma agreement.
• Other Income: None in 2025; \$26.6 million in 2024 due to the royalty liability mark-down.
• Warrant Issuance Cost: \$3.1 million expensed, \$2.6 million deducted from equity, allocated based on instrument fair value.

Bottom Line

• GAAP Net Loss: \$283.7 million for Q4 2025 (\$25.51 per share), driven by the large non-cash charges, compared to \$4.3 million loss in Q4 2024.
• Non-GAAP Adjusted Net Loss: \$7.1 million for Q4 2025 (\$0.64 per share), up from \$4.0 million in Q4 2024, excluding non-cash charges.
• Year-End 2025 Cash: \$82.4 million (up from \$21.5 million at end of 2024), providing significant funding runway.
• Total Liabilities: \$233.8 million at December 31, 2025 (up from \$62.8 million), due almost entirely to non-cash warrant and royalty liabilities. Excluding these, non-GAAP liabilities were just \$2.3 million, reflecting a low operating leverage.

Key Shareholder Takeaways & Price-Sensitive Information

• The upcoming Phase 3 trial for roluperidone represents a critical value inflection point for Minerva. Success could position the company as the leader in the treatment of negative symptoms of schizophrenia, an area with no approved therapies.
• Recent \$80 million capital raise, with the potential for up to \$120 million more, gives the company a strong cash runway through the next major clinical milestone and potential NDA resubmission. This reduces near-term financing risk and supports continued R&D investment.
• Non-cash accounting losses from the preferred stock/warrant transaction create headline net losses but do not impact actual cash burn or operational flexibility. Investors should focus on the company’s non-GAAP results, which more accurately reflect operating performance.
• The successful alignment with FDA for the Phase 3 trial design significantly de-risks the regulatory path forward.
• Upcoming events that may impact share price include: the start of the Phase 3 trial (Q2 2026), potential warrant exercises bringing in additional capital, and the release of topline data in H2 2027.

Strategic Outlook

• Minerva’s management believes that, strengthened by this financing and regulatory progress, it is well-positioned to complete the Phase 3 trial, resubmit its NDA, and, if successful, launch roluperidone in the U.S.
• If approved, roluperidone could “shift the treatment paradigm” for negative symptoms in schizophrenia, unlocking significant commercial and clinical value for shareholders.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should consult their own advisors and review all public filings before making investment decisions. This article may contain forward-looking statements that are subject to risks and uncertainties, including those discussed in Minerva Neurosciences’ latest SEC filings. Actual results may differ materially from those projected.

View Minerva Neurosciences, Inc. Historical chart here